| Name | Title | Contact Details |
|---|---|---|
Andreas Busch |
Chief Innovation Officer | Profile |
At BioNTech we believe that every cancer patient’s treatment should be individualized. Our vision is to provide patient-specific immunotherapies worldwide.
BH1 (Better Health for Everyone) is a Franklin, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Synthorx Inc. is a biotechnology company using synthetic biology to discover and develop novel protein therapeutics. Synthorx`s expanded genetic alphabet platform has the unique ability to drive the site-specific incorporation of multiple synthetic amino acids into proteins thereby tuning receptor specificity important for improving efficacy and safety. In addition, their engineered organisms provide the ability to manufacture these improved proteins, called Synthorins, with the required fidelity and yield. The unique Synthorx platform expands the chemical and structural repertoire of protein therapeutics and uncovers new ways to modulate pharmacological properties of biologics, not possible with other technologies. The company was founded based on important discoveries in Dr. Floyd Romesberg`s lab at The Scripps Research Institute in conjunction with Avalon Ventures, which housed Synthorx in its incubator, COI Pharmaceuticals, Inc. The company is headquartered in La Jolla, Calif.
Morphotek is a Exton, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Simcha Therapeutics uses directed evolution to engineer novel cytokines designed to unlock the precision and power of the immune system.